Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mingtao Chen"'
Publikováno v:
Journal of Oncology. 2022:1-15
The role of autophagy in cancer remains elusive, and nontargeted autophagy inhibitors have limited therapeutic effects in HNSCC. Here, we systematically analyzed the correlation of autophagy-related genes in HNSCC through TCGA and single-cell sequenc
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Objective Although perineural invasion (PNI) is well-known to be correlated with and able to predict lymph node metastasis (LNM) in oral squamous cell carcinoma (OSCC), the clinical and molecular correlation between PNI and LNM has not been elucidate
Autor:
Jianliang Shen, Chen Gao, Yufeng Liu, Zhiping Li, Zhijian Cao, Yongsheng Zhang, Maosheng Xu, Mingtao Chen, Feng Cui, Peipei Pang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 13, Pp 4240-4249 (2021)
Cancer Medicine, Vol 10, Iss 13, Pp 4240-4249 (2021)
Purpose To investigate whether preoperative histogram parameters of dynamic contrast‐enhanced MRI (DCE‐MRI) can assess the expression of Ki‐67 in prostate cancer (PCa). Materials and methods A consecutive series of 76 patients with pathology‐
Autor:
Lu Sun, Xiaoliang Jin, Liang Huang, Jing Zhao, Haifeng Jin, Mingtao Chen, Chunli Zhang, Bin Lu
Publikováno v:
Frontiers in oncology. 12
BackgroundChronic atrophic gastritis (CAG) can progress to gastric cancer (GC) thus requiring endoscopic surveillance. Here, we analyze various aspects of CAG progression, time, and mucosal background, to guide reasonable surveillance.MethodsCAG pati
Autor:
Meihua Li, Chengshan Niu, Mingtao Chen, Kaige Ji, Hui Xu, Shengli Dong, Yan Zhang, Qinguo Meng, Yuge Dou, Yijun Wang, Rui Wu, Yian Tu, Chao Zhou, Apeng Liang, Huan Wang, Rongzhen Ni, Aishen Gong, Hui Su, Mingyu Jiang, Feng Xing, Shaoqing Chen, Xiugui Chen, Jun Li, Yusheng Wu
Publikováno v:
Cancer Research. 83:5979-5979
The introduction of cyclin-dependent kinase (CDK) 4 and 6 dual inhibitors significantly improves the progression-free survival of patients with ER+/HER2- advanced or metastatic breast cancer. A large cohort of patients, however, eventually relapse to